Donald Cross, MD
Cardiovascular Disease · Waco, TXNPI 1447256110
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Philips North America LLC at 39.1% of the total. Reporting peaked in 2019 at $8,174 and has fallen 82.0% since, to $1,474 in 2025.
Across 204 payments — averaging $111.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$9K
- Boston Scientific$2K
- Medtronic$2K
- Penumbra, Inc.$1K
- Terumo Medical Corporation$1K
- Abiomed$1K
- plus $6K from 23 others
Across 47 payments — averaging $7391.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Currax Pharmaceuticals LLC$168K
- AstraZeneca$162K
- Alnylam Pharmaceuticals Inc.$11K
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim International GmbH$551
What the payments were for
- Consulting fees$1,2005%
- Speaking & faculty fees$6,00026%
- Travel & lodging$4,19718%
- Food & beverage$11,36250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 18 | $8,891 |
| Boston Scientific | 37 | $2,412 |
| Medtronic(2 entities) | 39 | $1,802 |
| Penumbra, Inc. | 5 | $1,455 |
| Terumo Medical Corporation | 10 | $1,311 |
| Abiomed | 13 | $1,212 |
| AstraZeneca | 9 | $1,174 |
| Abbott | 17 | $979 |
| Biotronik Inc. | 6 | $681 |
| Cardiovascular Systems Inc. | 9 | $651 |
| Shockwave Medical, Inc | 4 | $630 |
| Inari Medical, Inc. | 2 | $258 |
| Novartis | 9 | $217 |
| Johnson & Johnson | 2 | $213 |
| Bayer | 2 | $212 |
| Impulse Dynamics (USA) Inc. | 1 | $131 |
| Pfizer | 2 | $97 |
| Actelion Pharmaceuticals US, Inc. | 5 | $76 |
| Flowphysix Inc | 1 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| Novo Nordisk | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectranetics Undiv$6,000
- Indigo$1,306
- IGT_D Systems$1,279
- Impella$841
- (9520) IGT Devices Undivided$800
- AVVIGO Guidance System$669
- GLIDESHEATH SLENDER$659
- GlideWire$507
- Peripheral Orbital Atherectomy System$456
- CoreValve Evolut$401
- IGT D Peripheral$400
- GENERAL VASCULAR ACCESS$393
- ONYX FRONTIER$373
- Vascular Lithotripsy$354
- CARDIOMEMS$327
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$325
- OPTIMIZER$262
- Orsiro$258
- Pulsar$258
- PRO-Kinetic Energy$258
How this compares
$22,759 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 593 | $479,294 |
| XareltoRivaroxaban | 165 | $172,777 |
| EntrestoSacubitril/Valsartan | 152 | $128,024 |
| Repatha SureclickEvolocumab | 116 | $95,046 |
| FarxigaDapagliflozin Propanediol | 51 | $39,474 |
| JardianceEmpagliflozin | 51 | $38,880 |
| MultaqDronedarone Hcl | 18 | $17,944 |
| Praluent PenAlirocumab | 26 | $14,607 |
| Metoprolol Succinate | 745 | $11,681 |
| Ranolazine ErRanolazine | 112 | $8,007 |
| BrilintaTicagrelor | 13 | $7,967 |
| Atorvastatin Calcium | 521 | $6,279 |
| Rosuvastatin Calcium | 359 | $5,506 |
| ClopidogrelClopidogrel Bisulfate | 368 | $5,326 |
| Carvedilol | 657 | $4,985 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $97 | $479,294593 claims |
| Johnson & JohnsonXarelto | $213 | $172,777165 claims |
| NovartisEntresto | $217 | $128,024152 claims |
| AstraZenecaFarxiga, Brilinta | $1,174 | $47,44164 claims |
| Boehringer IngelheimJardiance | $23 | $38,88051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Waco
- Shawn SkeenWaco$104K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.